Cipla Limited stands as one of India’s oldest and most trusted names in the pharmaceutical industry. Founded in 1935 by visionary scientist Dr. Khwaja Abdul Hamied, Cipla began with a simple mission — to make medicines accessible and affordable to all. Over nine decades, this mission has grown into a global movement for healthcare equality.

Headquartered in Mumbai, India, Cipla operates in more than 80 countries, producing over 1,500 high-quality medicines across multiple therapeutic areas — including respiratory care, oncology, HIV/AIDS, diabetes, and cardiovascular health. Its products reach millions of patients every year, improving lives and expanding access to essential treatments.

Cipla earned worldwide recognition in the early 2000s when it made HIV/AIDS treatments affordable for developing nations. This bold move changed the global pharma landscape, proving that quality medicine could be both effective and affordable.

Today, Cipla continues its legacy of innovation through AI-driven research, biotechnology, and sustainable manufacturing. The company’s research centers focus on creating cost-effective drug formulations, while its green manufacturing initiatives reduce environmental impact.

Under its guiding purpose — “Caring for Life” — Cipla has transformed from a local drug manufacturer into a global healthcare leader. The brand’s compassionate approach, scientific expertise, and strong ethics have made it a role model for pharmaceutical innovation.

Cipla’s leadership team remains committed to advancing healthcare for all, combining technology, science, and humanity. From pioneering respiratory treatments to digital health initiatives, the company continues to inspire trust across generations and geographies.